NuCana is a clinical stage biopharmaceutical company developing and commercialising novel anti-cancer medicines. With its next generation of anti-cancer agents (nucleotide analogues), NuCana is setting new benchmarks for innovative therapeutic treatments. The state-of-the-art ProTide technology transforms existing therapies into better and safer medicines that overcome key cancer resistance mechanisms.
Company Growth (employees)
Type
Public
HQ
Edinburgh, GB
Founded
2008
Size (employees)
21 (est)+5%
NuCana was founded in 2008 and is headquartered in Edinburgh, GB

Key People/Management at NuCana

Hugh Griffith

Hugh Griffith

CEO
Ian Abercrombie

Ian Abercrombie

Chief Operating Officer
Chris Wood

Chris Wood

Executive Chairman

NuCana Office Locations

NuCana has offices in Edinburgh and Newton
Edinburgh, GB (HQ)
10 Lochside Place
Newton, US
Riverside Center 275 Grove St

NuCana Financials and Metrics

NuCana Financials

GBP

Net income (FY, 2016)

(6 m)

EBIT (FY, 2016)

(8.4 m)

Cash (31-Dec-2016)

20 m
GBPFY, 2014FY, 2015FY, 2016

R&D expense

2.7 m4.9 m7.9 m

General and administrative expense

1.1 m2 m1.1 m

Operating expense total

3.8 m6.9 m9 m

EBIT

(6.9 m)(8.4 m)
GBPFY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Cash

3.2 k759.2 k1 m6.4 m4.9 m36.4 m29.2 m20 m

Accounts Receivable

17.3 k185.8 k385.2 k561.8 k511.7 k639.5 k148.8 k21 k

Inventories

365.7 k

Current Assets

386.1 k945 k1.4 m6.9 m5.4 m37.1 m30.7 m25.8 m
    GBPFY, 2014FY, 2015FY, 2016

    Net Income

    (3.1 m)(5.3 m)(6 m)

    Depreciation and Amortization

    43.5 k101 k

    Accounts Receivable

    36.4 k(3.4 m)

    Accounts Payable

    133.1 k220 k
      Y, 2016

      Financial Leverage

      1.1 x
      Show all financial metrics

      NuCana's Web-traffic and Trends

      NuCana Online and Social Media Presence

      NuCana Company Life and Culture

      You may also be interested in